PF-Atlas › Clinical Trials › NCT07464912
A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis
TDI01 · Phase 3
Registry ID
NCT07464912
Phase
Phase 3
Status
Recruiting
Drug / intervention
TDI01
Sponsor
Beijing Tide Pharmaceutical Co., Ltd
Start
2025-12-24
Enrollment
508
Locations
1
About this trial
This study is a multicentre, randomised, double-blind, placebo-controlled, adaptive design clinical trial to evaluate the efficacy and safety of TDI01 suspension in the treatment of idiopathic pulmonary fibrosis (IPF). The study will be conducted in China and divided into two stages, both of which are multicentre, randomised, double-blind, placebo-controlled studies. Stage 1 aims to evaluate the efficacy and safety of TDI01 suspension compared to the placebo group in the treatment of IPF patients, and Stage 2 aims to further confirm the efficacy and safety of TDI01 suspension compared to the placebo group in the treatment of IPF patients.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT07464912 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.